Imperical Blog
FEBRUARY 27, 2024
With more than 65,000 clinical studies currently recruiting, our industry is constantly working hard to enroll participants and meet study timelines. Unfortunately, public skepticism in clinical trials can get in the way of those efforts. People enroll in studies for a variety of reasons, from… The post Overcoming Public Skepticism In Clinical Trials appeared first on Imperial Clinical Research Services Blog.
ACRP blog
FEBRUARY 26, 2024
If there wasn’t already a general awareness among the personnel of the Penn State Cancer Institute Clinical Trials Office that February is National Cancer Prevention Month , you may guess the fact that breast cancer survivor Doris Shank, BSN, MSN, administrative director of the office, is preparing for her second cancer-related surgery soon has brought the topic of prevention to mind for some of them in any event.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Antidote
FEBRUARY 28, 2024
Electronic patient-reported outcomes ( often abbreviated to ePRO ) are tools intended to collect patient data in clinical trials through methods such as diaries, phone apps, tablets, and other devices. These tools are useful for streamlining the work required by site staff and also create a more patient-centric environment in clinical trials.
pharmaphorum
MARCH 1, 2024
There is a pressing need for companies to transition their EU clinical trials that are ongoing under the “old” regulatory framework of the Clinical Trials Directive to the Clinical Trials Regulation. The risk for those that don’t meet the 30th January 2025 deadline for transition is that they will lose their legal basis.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Outsourcing Pharma
FEBRUARY 27, 2024
Last week (February 22), it was announced a recent survey conducted jointly by Climedo and Siteworks has shed light on the perspectives of more than 65 primarily European-based study physicians.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 27, 2024
Exports of drugs and pharmaceuticals during the month of January posted a growth of 6.84 per cent as compared to the same month of previous year. For the first 10 months of the current fiscal year pharma exports grew 8.07 per cent, according to the Central government.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Cloudbyz
FEBRUARY 29, 2024
In the dynamic landscape of pharmacovigilance, where timely and accurate data processing is paramount, the integration of artificial intelligence (AI) technologies has emerged as a game-changer. AI-enabled data extraction holds immense promise in expediting case processing within clinical trials, offering a transformative approach to streamline workflows and enhance efficiency.
pharmaphorum
FEBRUARY 28, 2024
Rare Disease Day is an opportunity to highlight the importance of enhancing clinical trial success in rare diseases for the benefit of patients.
Velocity Clinical Research
FEBRUARY 27, 2024
“[Patient centricity] is about taking those patient insights and their voice and translating them into actions. And that was really the impetus for what we saw in Velocity’s submission.” – Pat Roselle, Global Head of Patient Stakeholder Engagement at Sanofi. Thank you to Pat and Jimmy Bechtel for joining Nick Spittal to discuss the initiatives that earned Velocity the 2023 Society for Clinical Research Sites (SCRS) Excellence in Patient Centricity Award.
Pharmaceutical Technology
FEBRUARY 29, 2024
India’s Tata Institute has developed a tablet combining resveratrol and copper that has the potential to prevent the recurrence of cancer.
Bio Pharma Dive
FEBRUARY 27, 2024
The biotech’s drug led to significant weight loss in a Phase 2 trial, causing shares to double as analysts compared results to the marks set by drugs from Eli Lilly and Novo Nordisk.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 27, 2024
On the list of illnesses that nobody wants, cancer and HIV both rank pretty high, and Californian man Paul Edmonds had both. But ever since one particular treatment five years ago, he’s been free of both cancer and HIV.
Worldwide Clinical Trials
MARCH 1, 2024
With cost and timelines being two of the most significant factors influencing a study’s progression aside from efficacy and safety, master protocols offer an attractive option for study design. These designs facilitate streamlined trial logistics and centralized governance and create higher-quality data. But how do they work, and when are they appropriate?
Pharmaceutical Technology
FEBRUARY 26, 2024
Bayer’s oral tyrosine kinase inhibitor is currently in a Phase I trial estimated to enrol 460 patients.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Bio Pharma Dive
MARCH 1, 2024
The restructuring comes ahead of a key study readout for Gritstone, which, like Moderna, is developing a type of personalized vaccine for cancer.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 26, 2024
Do bacteria mutate randomly, or do they mutate for a purpose? Researchers have been puzzling over this conundrum for over a century. In 1943, microbiologist Salvador Luria and physicist turned biologist Max Delbrück invented an experiment to argue that bacteria mutated aimlessly.
Pharma Times
FEBRUARY 28, 2024
Breast cancer is responsible for around 47,000 new cases in England every year
Pharmaceutical Technology
FEBRUARY 28, 2024
AGTC-501 is in Phase II development for retinitis in the SKYLINE trial (NCT03316560) and addresses unmet needs within the retinitis space
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Bio Pharma Dive
FEBRUARY 26, 2024
Zealand shares rose by more than one-third on the data, which provide further evidence so-called incretin drugs could help treat people with the liver disease.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 28, 2024
It’s been over three years since scientists first found microplastics swimming in four different human placentas, and as it turns out, that was just the tip of the iceberg. A few years later, at the start of 2023, researchers announced they had found microscopic particles of plastic waste in no fewer than 17 different placentas.
Rethinking Clinical Trials
FEBRUARY 28, 2024
In this Friday’s PCT Grand Rounds, Joseph Doyle of the Massachusetts Institute of Technology (MIT) will present “Effect of an Intensive Food-as-Medicine Program on Health and Healthcare Use: Evidence From a Randomized Clinical Trial.” The Grand Rounds session will be held on Friday, March 1, 2024, at 1:00 pm eastern. Doyle is the Erwin H.
Pharmaceutical Technology
FEBRUARY 29, 2024
LUT014 is being investigated in an ongoing Phase II trial as a first-line treatment for EGFR inhibitor-induced acneiform rash, for which there is no approved drug.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Bio Pharma Dive
MARCH 1, 2024
The expert committee is discussing whether, for certain older adults, to make a universal recommendation for vaccination, rather than the current policy of “shared decisionmaking.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 29, 2024
Even small doses of LSD could have therapeutic benefits for mental health and task performance, a new study shows. Researchers from the US and Germany gave 21 adults either a placebo or 13 or 26 micrograms of LSD – small doses that rarely lead to hallucinatory effects.
Fierce Pharma
FEBRUARY 29, 2024
In what CEO Albert Bourla called an update to a top priority at Pfizer, the company on Thursday systemically laid out its new oncology strategy following the $43 billion acquisition of antibody-dru | Pfizer on Thursday systemically laid out its new oncology strategy following the $43 billion acquisition of Seagen. The company aims to have at least eight blockbuster cancer drugs by 2030, with a focus on four main cancer types.
Pharmaceutical Technology
MARCH 1, 2024
During 2023, funding decreased by 43.2% compared to 2022 and by 52.3% compared to 2021, attributed to macroeconomic pressures.
Bio Pharma Dive
MARCH 1, 2024
Reeling from a difficult year financially, the pharma unveiled a new oncology division it says will produce eight billion-dollar medicines by 2030.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 26, 2024
The Department-related Parliamentary Standing Committee on Health and Family Welfare has recommended to the government to persuade private insurance companies to include Ayurveda, Yoga, Unani, Siddha and Homoeopathy (Ayush) treatments in their products and look at global acceptance for these systems of medicines through legalisation and insurance support in other countries.
Pharma Times
FEBRUARY 29, 2024
Aphasia is a language disorder caused by some form of brain damage, including stroke
Pharmaceutical Technology
FEBRUARY 28, 2024
Pelage Pharmaceuticals has secured $16.75m in a Series A financing round to further the development of PP405 for hair loss.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
59 
Let's personalize your content